0000899243-22-014117.txt : 20220406 0000899243-22-014117.hdr.sgml : 20220406 20220406165958 ACCESSION NUMBER: 0000899243-22-014117 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220404 FILED AS OF DATE: 20220406 DATE AS OF CHANGE: 20220406 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lee Yuchun CENTRAL INDEX KEY: 0001334365 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 22811170 MAIL ADDRESS: STREET 1: 170 TRACER LA. CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-04 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001334365 Lee Yuchun C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 0 0 0 Common Stock 2022-04-04 4 M 0 2000 81.54 A 3875 D Common Stock 2022-04-04 4 S 0 100 265.83 D 3775 D Common Stock 2022-04-04 4 S 0 917 267.23 D 2858 D Common Stock 2022-04-04 4 S 0 983 268.36 D 1875 D Common Stock 2022-04-05 4 M 0 2000 81.54 A 3875 D Common Stock 2022-04-05 4 S 0 17 268.30 D 3858 D Common Stock 2022-04-05 4 S 0 334 270.05 D 3524 D Common Stock 2022-04-05 4 S 0 488 271.94 D 3036 D Common Stock 2022-04-05 4 S 0 600 272.60 D 2436 D Common Stock 2022-04-05 4 S 0 100 273.50 D 2336 D Common Stock 2022-04-05 4 S 0 461 274.66 D 1875 D Stock Option (Right to Buy) 81.54 2022-04-04 4 M 0 2000 81.54 D 2023-05-31 Common Stock 2000 18000 D Stock Option (Right to Buy) 81.54 2022-04-05 4 M 0 2000 81.54 D 2023-05-31 Common Stock 2000 16000 D Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1. Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $267.23 (range $266.85 to $267.79). Open market sales reported on this line occurred at a weighted average price of $268.36 (range $267.97 to $268.81). Open market sales reported on this line occurred at a weighted average price of $270.05 (range $269.79 to $270.64). Open market sales reported on this line occurred at a weighted average price of $271.94 (range $271.35 to $272.27). Open market sales reported on this line occurred at a weighted average price of $272.60 (range $272.36 to $273.34). Open market sales reported on this line occurred at a weighted average price of $274.66 (range $274.63 to $274.68). Fully vested. Exhibit List: Exhibit 24 - Power of Attorney /s/ Sabrina Yohai, Attorney-in-Fact 2022-04-06 EX-24 2 attachment1.htm EX-24 DOCUMENT
                               POWER OF ATTORNEY

     The undersigned hereby constitutes and appoints each of Joy Liu, Sabrina
Yohai, Omar White, and Christiana Stevenson of Vertex Pharmaceuticals
Incorporated (the "Company"),  signing singly, with full power of substitution,
the undersigned's true and lawful attorney-in-fact to:

     1.  execute for and on behalf of the undersigned, in the undersigned's
         capacity as an officer, director and/or 10% shareholder of the Company,
         forms and authentication documents for EDGAR Filing Access;

     2.  do and perform any and all acts for and on behalf of the undersigned
         which may be necessary or desirable to complete and execute any such
         forms and authentication documents;

     3.  execute for and on behalf of the undersigned, in the undersigned's
         capacity as an officer, director and/or 10% shareholder of the
         Company, Forms 3, 4 and 5 in accordance with Section 16(a) of the
         Securities Exchange Act of 1934 and the rules thereunder;

     4.  do and perform any and all acts for and on behalf of the undersigned
         which may be necessary or desirable to complete and execute any such
         Form 3, 4 or 5 and timely file such form with the United States
         Securities and Exchange Commission and any stock exchange or similar
         authority; and

     5.  take any other action of any type whatsoever in connection with the
         foregoing which, in the opinion of such attorney-in-fact, may be of
         benefit to, in the best interests of, or legally required by the
         undersigned, it being understood that the documents executed by such
         attorney-in-fact on behalf of the undersigned pursuant to this Power of
         Attorney shall be in such form and shall contain such terms and
         conditions as such attorney-in-fact may approve in such attorney-in
         fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's  substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact,  in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of or transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

This Power of Attorney is intended to constitute a "confirming statement" for
presentation to the Securities and Exchange Commission as contemplated by
Instruction 7(a) of Forms 3, 4 and 5.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed this 1st day of January, 2022.


/s/ Yuchun Lee
-----------------------
Yuchun Lee